Master of Science in Biomedical Sciences / Department of Anatomy and Physiology / Mark L. Weiss / The traditional cell culture method after isolation from the body involves growing cells in 2 dimensions on plastic culture plate. However, the natural structure and physiology is 3 dimensions. To mimic in vivo environment, there has an increasing interest to find the way to maintain physiological properties. Here, we describe culturing human umbilical cord mesenchymal stromal cells (HUC-MSCs_in 3D setting using human platelet lysate gel. This gel is a fibrin-based structure like a blood clot. The preparation step of human platelet lysate (HPL) is by freeze- thaw cycles in order to release factors important for cells to grow and expand. Using of HPL to substitute for fetal bovine serum reduces potential cross contamination between species and xenogenicity. To maintain HPL media as a liquid, we add the anticoagulant heparin. Without adding anticoagulant, the gel will form. The aim of this study is to retrieve HUC-MSCs from HPL gel using Nattokinase, to characterize HUC-MSCs following the International Society for Cell Therapy’s MSC criteria, and to test a 3D invasion model with HPL-gel based structure. The result shows that using 1.75% Nattokinase at 60 minutes can recover the cells without reducing cell number and viability. After Nattokinase treatment, cells are able to attach to plastic and to increase in number. Moreover, they are able to differentiate into fat, bone, and cartilage no different from cells grown in 2D culture. However, to test surface markers by flow cytometry, all MSC markers are positive except CD 105. They are also positive of cell surface markers that should be negative. When seeded back to 2D culture for an additional passage, the MSCs meet ISCT criteria the same as control.

Regenerative medicine is an emerging technology and with hundreds of cell therapies currently in clinical trials there is a need to expand the limited knowledge related to their storage, shipment and preservation. The most widely used medium for human cell cryopreservation is 10%wt dimethyl sulfoxide (DMSO) in serum. However given its potential toxicity, DMSO usage is a key issue in cryopreservation. Methods specify the need to reduce cell exposure time to DMSO above 0°C as much as possible but the maximum amount of time cells can be exposed to DMSO to prevent a detrimental effect needs to be clarified. There are also regulatory issues and concerns with the xenotoxicity, ethics and supply of the other core component in the standard cryomedia formulation: Foetal Bovine Serum (FBS). Developing a viable alternative to FBS is crucial. In cryobiology literature thawing appears poorly understood. A stable process is as vital as freezing to prevent injury to cells. Protocols are currently too vague for cell therapy regulation and need improvement. The time dependent DMSO cytotoxicity was evaluated by overexposing cells to DMSO during and/or after cryopreservation. A broad investigation found that after 1 hour overexposure post thaw viability of human mesenchymal stem cells (hMSCs) was reduced from 96.3±0.6% to 74.1±4.0% and the co-expression of five key hMSC markers was changed from 97.9±1.3% to 68.3±2.6%. This significant change could cause indicate a change in product efficacy and affect patient health, to prevent this, DMSO exposure must be kept to below 1 hour. A range of alternative vehicle solutions were screened and human platelet lysate (hPL) investigated as an alternative. In depth experimentation with hPL as a cryopreservation vehicle solution and culture supplement (in place of FBS) found it to be a worthy, statistically similar alternative. With no xenological or ethical concerns, lower costs than other serum-free alternatives hPL could allow for a move away from xenological components. A heat transfer model was developed and determined that 720J is required to thaw a vial. Using the heat transfer model and additional factors such as pre-thaw stabilisation and on thaw dilution, a two-stage experiment found that the current standard process (warming in a 37°C waterbath) within the current paradigm of a 1.8mL cryovial is optimal but further work is required to define the process for scaled-up product.

Epitélios confluentes de queratinócitos autólogos, cultivados segundo metodologia padronizada por Rheinwald e Green em 1975, têm sido usados como enxertos em diferentes situações clínicas. Contudo, a presença de componentes xenobióticos empregados nesta metodologia implica na possibilidade de transmissão de zoonoses, príons e viroses aos pacientes, além de envolver questões éticas relacionadas à utilização de animais. Tais preocupações têm direcionado pesquisadores a buscar alternativas que superem este impasse; no entanto, as formulações obtidas até o momento não são completamente satisfatórias. Assim, nossa proposta neste estudo, foi omitir ou substituir os componentes xenobióticos tradicionalmente utilizados no meio para queratinócitos, por similares humanos. Como resultado, padronizamos um meio de cultura onde omitimos o emprego de toxina colérica, substituímos o soro fetal bovino por lisado de plaquetas humanas na concentração de 2,5% e a insulina de origem bovina foi substituída por insulina recombinante humana na mesma concentração do método original (5 μg/mL). Com os resultados obtidos foi possível concluir ser viável o cultivo de queratinócitos humanos, mantidos em meio de cultura livre de componentes xenobióticos. / Confluent epithelia of autologous keratinocytes, cultivated according to standardized methodology by Rheinwald and Green in 1975, have been used as grafts in different clinical situations. However, the presence of xenobiotics components applied in this method implies the possibility of transmission of zoonoses, príons, and viruses to patients, besides involving ethical issues related to the use of animals for components obtainment. Such concerns have driven researchers to seek alternatives that overcome this deadlock, as the formulations obtained so far are not completely satisfactory. Thus, our proposal in this study was to omit or replace the xenobiotics components traditionally used in the medium to keratinocytes culture, by human similar. As a result, we have standardized a culture medium whereby we omitted the use of cholera toxin, replaced fetal bovine serum by human platelet lysate at a 2.5% concentration and bovine insulin was replaced by recombinant human insulin at the same concentration as the original method (5 μg/mL). With the results obtained we could conclude that the method to be viable to cultivate human keratinocytes, kept in culture medium free of xenobiotics components.

Epitélios confluentes de queratinócitos autólogos, cultivados segundo metodologia padronizada por Rheinwald e Green em 1975, têm sido usados como enxertos em diferentes situações clínicas. Contudo, a presença de componentes xenobióticos empregados nesta metodologia implica na possibilidade de transmissão de zoonoses, príons e viroses aos pacientes, além de envolver questões éticas relacionadas à utilização de animais. Tais preocupações têm direcionado pesquisadores a buscar alternativas que superem este impasse; no entanto, as formulações obtidas até o momento não são completamente satisfatórias. Assim, nossa proposta neste estudo, foi omitir ou substituir os componentes xenobióticos tradicionalmente utilizados no meio para queratinócitos, por similares humanos. Como resultado, padronizamos um meio de cultura onde omitimos o emprego de toxina colérica, substituímos o soro fetal bovino por lisado de plaquetas humanas na concentração de 2,5% e a insulina de origem bovina foi substituída por insulina recombinante humana na mesma concentração do método original (5 μg/mL). Com os resultados obtidos foi possível concluir ser viável o cultivo de queratinócitos humanos, mantidos em meio de cultura livre de componentes xenobióticos. / Confluent epithelia of autologous keratinocytes, cultivated according to standardized methodology by Rheinwald and Green in 1975, have been used as grafts in different clinical situations. However, the presence of xenobiotics components applied in this method implies the possibility of transmission of zoonoses, príons, and viruses to patients, besides involving ethical issues related to the use of animals for components obtainment. Such concerns have driven researchers to seek alternatives that overcome this deadlock, as the formulations obtained so far are not completely satisfactory. Thus, our proposal in this study was to omit or replace the xenobiotics components traditionally used in the medium to keratinocytes culture, by human similar. As a result, we have standardized a culture medium whereby we omitted the use of cholera toxin, replaced fetal bovine serum by human platelet lysate at a 2.5% concentration and bovine insulin was replaced by recombinant human insulin at the same concentration as the original method (5 μg/mL). With the results obtained we could conclude that the method to be viable to cultivate human keratinocytes, kept in culture medium free of xenobiotics components.

Master of Science in Biomedical Sciences / Department of Anatomy and Physiology / Mark L. Weiss / Mesenchymal stromal cells (MSCs) derived from the umbilical cord (UC-MSCs) have therapeutic applications and are studied to understand their potential uses and immunomodulatory properties. Research must identify good manufacturing process (GMP) compliant methods to isolate and expand UC-MSCs. In addition, MSCs metabolism characteristics in culture are unknown, warranting further investigation. Viability of MSCs decreases after cryopreservation, which is detrimental to clinical translation. Previously published methods used to isolate MSCs from the umbilical cord included open dissection steps and xenogeneic components. Here, I developed improved methods by eliminating dissection which reduces contamination risks. Instead, I used the whole umbilical cord and Miltenyi dissociator tubes to mechanically and enzymatically dissociate cells in a closed system. Xenogeneic components were decreased by using medium containing pooled human platelet lysate instead of fetal bovine serum. The cell numbers isolated from umbilical cord averaged 2.68 x 10⁵ per cm, which represents greater than 20 fold improvement over the previous method. Moreover, expansion cell numbers were increased using 10% pooled human platelet lysate supplemented media. The UC-MSCs generated here met the International Society of Cell Therapy (ISCT) definition of MSCs. Metabolism characteristics of MSCs indicated that glucose was the critical metabolite, maintaining cells longer in culture than glutamine. Cell death followed depletion of glucose, too. Finally, the average viability after thawing cryopreserved MSCs was more than 95%, higher than previous methods. The improvements I introduced to our methodology could speed clinical translation of MSCs as an allogeneic cellular therapy

No description available.

Successful translation of multipotent mesenchymal stromal cell (MSC)-based therapies into clinical reality relies on adequate cell production procedures. These should be available not only for human MSC, but also for MSC from animal species relevant to preclinical research and veterinary medicine. The cell culture medium supplementation is one of the critical aspects in MSC production. Therefore, we previously established a scalable protocol for the production of buffy-coat based equine platelet lysate (ePL). This ePL proved to be a suitable alternative to fetal bovine serum (FBS) for equine adipose-derived (AD-) MSC culture so far, as it supported AD-MSC proliferation and basic characteristics. The aim of the current study was to further analyze the functional properties of equine AD-MSC cultured with the same ePL, focusing on cell fitness, genetic stability and pro-angiogenic potency. All experiments were performed with AD-MSC from n = 5 horses, which were cultured either in medium supplemented with 10% FBS, 10% ePL or 2.5% ePL. AD-MSC cultured with 2.5% ePL, which previously showed decreased proliferation potential, displayed higher apoptosis but lower senescence levels as compared to 10% ePL medium (p < 0.05). Non-clonal chromosomal aberrations occurred in 8% of equine AD-MSC cultivated with FBS and only in 4.8% of equine AD-MSC cultivated with 10% ePL. Clonal aberrations in the AD-MSC were neither observed in FBS nor in 10% ePL medium. Analysis of AD-MSC and endothelial cells in an indirect co-culture revealed that the ePL supported the pro-angiogenic effects of AD-MSC. In the 10% ePL group, more vascular endothelial growth factor (VEGF-A) was released and highest VEGF-A concentrations were reached in the presence of ePL and co-cultured cells (p < 0.05). Correspondingly, AD-MSC expressed the VEGF receptor-2 at higher levels in the presence of ePL (p < 0.05). Finally, AD-MSC and 10% ePL together promoted the growth of endothelial cells and induced the formation of vessel-like structures in two of the samples. These data further substantiate that buffy-coat-based ePL is a valuable supplement for equine AD-MSC culture media. The ePL does not only support stable equine AD-MSC characteristics as demonstrated before, but it also enhances their functional properties.

Simple Summary Regenerative medicine using platelet-based blood products or adult stem cells offers the prospect of better clinical outcomes with many diseases. In veterinary medicine, most progress has been made with the development and therapeutic use of these regenerative therapeutics in horses, but the clinical need is given in dogs as well. Our aim was to transfer previous advances in the development of horse regenerative therapeutics, specifically the use of platelet lysate for feeding stem cell cultures, to the dog. Here, we describe the scalable production of canine platelet lysate, which could be used in regenerative biological therapies. We also evaluated the canine platelet lysate for its suitability in feeding canine stem cell cultures in comparison to equine platelet lysate used for equine stem cell cultures. Platelet lysate production from canine blood was successful, but the platelet lysate did not support stem cell culture in dogs in the same beneficial way observed with the equine platelet lysate and stem cells. In conclusion, canine platelet lysate can be produced in large scales as described here, but further research is needed to improve the cultivation of canine stem cells. Abstract Platelet lysate (PL) is an attractive platelet-based therapeutic tool and has shown promise as xeno-free replacement for fetal bovine serum (FBS) in human and equine mesenchymal stromal cell (MSC) culture. Here, we established a scalable buffy-coat-based protocol for canine PL (cPL) production (n = 12). The cPL was tested in canine adipose MSC (n = 5) culture compared to FBS. For further comparison, equine adipose MSC (n = 5) were cultured with analogous equine PL (ePL) or FBS. During canine blood processing, platelet and transforming growth factor-β1 concentrations increased (p < 0.05 and p < 0.001), while white blood cell concentrations decreased (p < 0.05). However, while equine MSC showed good results when cultured with 10% ePL, canine MSC cultured with 2.5% or 10% cPL changed their morphology and showed decreased metabolic activity (p < 0.05). Apoptosis and necrosis in canine MSC were increased with 2.5% cPL (p < 0.05). Surprisingly, passage 5 canine MSC showed less genetic aberrations after culture with 10% cPL than with FBS. Our data reveal that using analogous canine and equine biologicals does not entail the same results. The buffy-coat-based cPL was not adequate for canine MSC culture, but may still be useful for therapeutic applications.

Natural Killer (NK) cells can recognize and lyse a large variety of tumor cells and have been of interest as a potential cancer treatment option. Our group has developed a particle-based NK cell expansion method that utilizes plasma membrane particles (PM-particles) derived from K562 cells genetically engineered to express membrane bound IL21 and 41BBL(K562-mbIL21-41BBL), two proteins that stimulate growth and activity of NK cells. This method selectively expands highly cytotoxic NK cells > 400-fold in 14 days of culture. Currently NK cells are expanded in vitro using Fetal Bovine Serum (FBS) as a serum-supplement to promote cell growth. While effective, the use of animal products is not preferred in cell cultures grown for clinical purposes. This project tested Human Platelet Lysates (HPL) as a potential replacement for FBS in NK cell culture. NK cells were expanded using PM21-particle based expansion method with either FBS or HPL as supplements. Their growth characteristics, phenotype and functionality were assessed and compared. Results of this study determined that HPL is a viable option to replace FBS in NK cell culture for clinical applications, as there was no significant difference between the two serum supplements.

Translation of multipotent mesenchymal stromal cell (MSC)-based therapies is advancing in human and veterinary medicine. One critical issue is the in vitro culture of MSC before clinical use. Using fetal bovine serum (FBS) as supplement to the basal medium is still the gold standard for cultivation of many cell types including equine MSC. Alternatives are being explored, with substantial success using platelet lysate-supplemented media for human MSC. However, progress lags behind in the veterinary field. The aim of this study was to establish a scalable protocol for equine platelet lysate (ePL) production and to test the ePL in equine MSC culture. Whole blood was harvested into blood collection bags from 20 healthy horses. After checking sample materials for pathogen contamination, samples from 19 animals were included. Platelet concentrates were prepared using a buffy coat method. Platelets, platelet-derived growth factor BB, and transforming growth factor b1 concentrations were increased in the concentrates compared with whole blood or serum (p < 0.05), while white blood cells were reduced (p < 0.05). The concentrates were lysed using freeze/thaw cycles, which eliminated the cells while growth factor concentrations were maintained. Donor age negatively correlated with platelet and growth factor concentrations after processing (p < 0.05). Finally, all lysates were pooled and the ePL was evaluated as culture medium supplement in comparison with FBS, using adipose-derived MSC from four unrelated donor horses. MSC proliferated well in 10% FBS as well as in 10% ePL. However, using 5 or 2.5% ePL entailed highly inconsistent proliferation or loss of proliferation, with significant differences in generation times and confluencies (p < 0.05). MSC expressed the surface antigens CD90, CD44, and CD29, but CD73 and CD105 detection was low in all culture media. Adipogenic and osteogenic differentiation led to similar results in MSC from different culture media. The buffy coat method is useful to produce equine platelet concentrate with increased platelet and reduced white blood cell content in large scales. The ePL obtained supports MSC expansion similar as FBS when used at the same concentration (10%). Further investigations into equine MSC functionality in culture with ePL should follow.